FY2024 EPS Estimates for BCAX Reduced by Cantor Fitzgerald

Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Stock analysts at Cantor Fitzgerald lowered their FY2024 earnings per share (EPS) estimates for shares of Bicara Therapeutics in a research note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst E. Schmidt now forecasts that the company will post earnings per share of ($2.12) for the year, down from their previous estimate of ($1.61). Cantor Fitzgerald currently has a "Overweight" rating on the stock. The consensus estimate for Bicara Therapeutics' current full-year earnings is ($2.89) per share.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.60) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($1.14).

A number of other analysts have also recently weighed in on the company. Rodman & Renshaw initiated coverage on Bicara Therapeutics in a research report on Tuesday, November 5th. They issued a "buy" rating and a $48.00 price target for the company. TD Cowen initiated coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set a "buy" rating for the company. RODMAN&RENSHAW raised Bicara Therapeutics to a "strong-buy" rating in a research report on Tuesday, November 5th. Stifel Nicolaus initiated coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set a "buy" rating and a $47.00 price objective for the company. Finally, Morgan Stanley assumed coverage on Bicara Therapeutics in a research report on Tuesday, October 8th. They set an "overweight" rating and a $35.00 price objective for the company. Five analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Bicara Therapeutics presently has a consensus rating of "Buy" and an average price target of $43.33.

Bicara Therapeutics Trading Down 4.8 %

Shares of BCAX stock traded down $0.98 on Monday, reaching $19.20. 368,995 shares of the company's stock traded hands, compared to its average volume of 357,659. The company has a 50 day moving average of $23.33. Bicara Therapeutics has a 12-month low of $18.33 and a 12-month high of $28.09.

Insider Activity

In other Bicara Therapeutics news, major shareholder James E. Flynn purchased 70,000 shares of the firm's stock in a transaction that occurred on Tuesday, September 17th. The shares were acquired at an average cost of $18.00 per share, for a total transaction of $1,260,000.00. Following the transaction, the insider now directly owns 897,587 shares in the company, valued at approximately $16,156,566. The trade was a 8.46 % increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this link. Also, Director Ra Capital Management, L.P. purchased 1,833,000 shares of the firm's stock in a transaction that occurred on Monday, September 16th. The shares were acquired at an average price of $18.00 per share, for a total transaction of $32,994,000.00. Following the completion of the transaction, the director now owns 4,303,418 shares in the company, valued at $77,461,524. The trade was a 74.20 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Institutional Investors Weigh In On Bicara Therapeutics

Large investors have recently bought and sold shares of the business. Cinctive Capital Management LP bought a new stake in Bicara Therapeutics during the 3rd quarter worth approximately $229,000. Barclays PLC acquired a new position in Bicara Therapeutics during the 3rd quarter worth $255,000. Jane Street Group LLC acquired a new position in Bicara Therapeutics during the 3rd quarter worth $309,000. Teachers Retirement System of The State of Kentucky acquired a new position in Bicara Therapeutics during the 3rd quarter worth $358,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Bicara Therapeutics during the 3rd quarter worth $462,000.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.